Director Market Access
Illumina
Director Market Access
Illumina
Develops sequencing platforms and consumables
The Director, Market Access – CMS Coverage & Reimbursement Policy will lead the company's strategy for Medicare coverage, coding, reimbursement, and federal payment policy affecting genomic sequencing and genetic testing. This individual will serve as the company's primary expert on CMS coverage policy, Medicare Administrative Contractors (MACs), coding processes, reimbursement methodologies, and federal regulatory developments impacting access to genomic sequencing and genetic testing.
Working closely with Government Affairs, Medical Affairs, HEOR, Clinical Affairs, Regulatory Affairs, and Commercial teams, this leader will develop evidence-based strategies that improve Medicare beneficiary access while shaping national reimbursement policy.
Approximately 25–35% travel.
The estimated base salary range for the Director, Market Access – CMS Coverage & Reimbursement Policy role based in the United States of America is: $187,400 - $281,000. Should the level or location of the role change during the hiring process, the applicable base pay range may be updated accordingly. The range reflects long‑term growth in the role; therefore, most candidates are hired between the minimum and middle of the range. Placement depends on experience, skills, location, and internal equity. Additionally, all employees are eligible for one of our variable cash programs (bonus or commission) and eligible roles may receive equity as part of the compensation package. We offer a wide range of benefits as innovative as our work, including access to genomics sequencing, family planning, health/dental/vision, retirement benefits, and paid time off.Illumina develops and sells integrated sequencing systems and the consumables needed to analyze genetic variation and biological function. Its instruments use sequencing-by-synthesis on flow-cell-based platforms, with specialized reagents and library preparation kits that are consumed per run. The company differentiates itself through a broad end-to-end ecosystem, a large installed base that drives repeat purchases, and strategic acquisitions that expand capabilities into multiomics and clinical applications. Its goal is to advance genomic analysis for research and clinical diagnostics to enable personalized medicine and early cancer detection.
Explore more opportunities at Illumina